An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
Phase 1
- Conditions
- COVID-19Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2020-001366-11-IE
- Lead Sponsor
- World Health Organisation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 100000
Inclusion Criteria
oadults (age =18 years, which allows consent),
orecently hospitalised (or already in hospital) with laboratory-confirmed COVID,
onot expected to be transferred within 72 hours,
owith, in the view of their doctors, no contra-indication to any potentially relevant study drug.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 800
Exclusion Criteria
Under 18 years of age
Known allergy or contra-indications to any of the investigational products
Anticipated transfer within 72 hours to a non-study hospital.
Positive Pregnancy test
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method